This database contains 114 studies, archived under the term: "baseline"
Click here to filter this large number of results.
Transcranial Magnetic Stimulation to Address Mild Cognitive Impairment in the Elderly: A Randomized Controlled Study
Drumond Marra, Hellen Livia,
Myczkowski, Martin Luiz,
Maia Memória, Cláudia,
Arnaut, Débora,
Leite Ribeiro, Philip,
Sardinha Mansur, Carlos Gustavo,
Lancelote Alberto, Rodrigo,
Boura Bellini, Bianca,
Alves Fernandes da Silva, Adriano,
Tortella, Gabriel,
Ciampi de Andrade, Daniel,
Teixeira, Manoel Jacobsen,
Forlenza, Orestes Vicente,
Marcolin, Marco Antonio
Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technique with potential to improve memory. Mild cognitive impairment (MCI), which still lacks a specific therapy, is a clinical syndrome associated with increased risk of dementia. This study aims to assess the effects of high-frequency repetitive TMS (HF rTMS) on everyday memory of the elderly with […]
The PACE study: a randomized clinical trial of cognitive activity strategy training for older people with mild cognitive impairment
Vidovich, Mandy R.,
Lautenschlager, Nicola T.,
Flicker, Leon,
Clare, Linda,
McCaul, Kieran,
Almeida, Osvaldo P.
Objective: The role of cognition-focused interventions in reducing cognitive decline in older people remains uncertain. This study aimed to clarify whether a group cognitive activity (CA) strategy-training program would decrease the 2-year rate of cognitive decline of people with mild cognitive impairment (MCI).; Design: Randomized controlled trial.; Setting: One study site.; Participants: 160 older adults […]
Evaluating rivastigmine in mild-to-moderate Parkinson’s disease dementia using ADAS-cog items
Schmitt, Frederick A.,
Aarsland, Dag,
Brønnick, Kolbjørn S.,
Meng, Xiangyi,
Tekin, Sibel,
Olin, Jason T.
Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale—cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for […]
No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer’s disease
Objective: Work in experimental animals suggests that an interaction with dopaminergic networks might explain some of the therapeutic effects of the cholinesterase inhibitor class of drugs. This study aimed to test whether acute (single 5 mg) or 4–8 weeks (5–10 mg) of treatment with oral donepezil would elicit measurable striatal dopamine (DA) release in patients […]
Vitamins B₁₂, B₆, and folic acid for cognition in older men
Ford, A. H.,
Flicker, L.,
Alfonso, H.,
Thomas, J.,
Clarnette, R.,
Martins, R.,
Almeida, O. P.
[Correction Notice: An erratum for this article was reported in Vol 77(8) of Neurology (see record [rid]2011-21984-022[/rid]). In the original article, the daily dose of vitamin B12 used in the trial was reported as 400 μg, but it should have been 500 μg.] Objective: To investigate whether supplementing older men with vitamins B12, B6, and […]
Long-term treatment of patients with Alzheimer’s disease in primary and secondary care: Results from an international survey
Froelich, Lutz,
Andreasen, Niels,
Tsolaki, Magda,
Foucher, Arnaud,
Kavanagh, Shane,
Van Baelen, Bart,
Schwalen, Susanne
Objective: The International Outcomes Survey in Dementia (IOSID) was initiated to observe the effects of current standard of care for Alzheimer’s disease (AD) on patient outcomes and caregiver burden in a real-life setting. Research design and methods: This 2-year, international, prospective, longitudinal and observational cohort survey involved patients with mild-to-moderate AD (Mini-Mental State Examination [MMSE] […]
Efficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer’s disease: Results of a randomized, double‐blind, controlled trial investigating three dosages of cerebrolysin
Alvarez, X. A.,
Cacabelos, R.,
Sampedro, C.,
Aleixandre, M.,
Linares, C.,
Granizo, E.,
Doppler, E.,
Moessler, H.
Background: Cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimer’s disease (AD) (ITT data set: N = 133; MMSE: 14–20) included in a dose‐finding study (ITT data set: N = 251; MMSE: 14–25). Results of the […]
Effects of Chinese medicine for promoting blood circulation and removing blood stasis in treating patients with mild to moderate vascular dementia: a randomized, double-blind and parallel-controlled trial
Wei, Ming-qing,
Tian, Jin-zhou,
Shi, Jing,
Ma, Fu-yun,
Miao, Ying-chun,
Wang, Yong-yan
Background: Vascular dementia (VaD) is the second common subtype of dementia after Alzheimer’s disease. However, there is still a lack of medication that demonstrates clinically relevant symptomatic improvement. Static blood obstructing the brain is the main Chinese medicine syndrome of VaD.; Objective: To evaluate the effects of Chinese medicine for promoting blood circulation and removing […]
The effects of ramipril in individuals at risk for Alzheimer’s disease: results of a pilot clinical trial
Wharton, Whitney,
Stein, James H.,
Korcarz, Claudia,
Sachs, Jane,
Olson, Sandra R.,
Zetterberg, Henrik,
Dowling, Maritza,
Ye, Shuyun,
Gleason, Carey E.,
Underbakke, Gail,
Jacobson, Laura E.,
Johnson, Sterling C.,
Sager, Mark A.,
Asthana, Sanjay,
Carlsson, Cynthia M.
Research shows that certain antihypertensives taken during midlife confer Alzheimer’s disease (AD) related benefits in later life. We conducted a clinical trial to evaluate the extent to which the angiotensin converting enzyme inhibitor (ACE-I), ramipril, affects AD biomarkers including cerebrospinal fluid (CSF) amyloid-β (Aβ) levels and ACE activity, arterial function, and cognition in participants with […]